Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective

Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi

Clin Mol Hepatol. 2023;29(2):242-251. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0102

View: 1142 Download: 119

Letter to the Editor

Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs

Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):269-272. Published online February 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0040

View: 2893 Download: 257 Citations: 4

Editorial

Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis

Takumi Kawaguchi, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):177-180. Published online August 26, 2021

DOI: https://doi.org/10.3350/cmh.2021.0246

View: 3049 Download: 133 Citation: 1

Review

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):150-163. Published online November 10, 2021

DOI: https://doi.org/10.3350/cmh.2021.0310

View: 4504 Download: 299 Citations: 27

Letter to the Editor

Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma

Shigeo Shimose, Shunji Koya, Takumi Kawaguchi, Keisuke Hirota, Sachiyo Yoshio, Takashi Niizeki, Hiroo Matsuse, Takuji Torimura

Clin Mol Hepatol. 2021;27(4):616-619. Published online September 13, 2021

DOI: https://doi.org/10.3350/cmh.2021.0258

View: 3188 Download: 182 Citations: 2

Review

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity

Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi

Received November 9, 2022 Accepted February 9, 2023

DOI: https://doi.org/10.3350/cmh.2022.0391 [Epub ahead of print]

View: 715 Download: 142 Citations: 2

1 |

Viewed By 4165	Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Viewed By 3570	Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection
Viewed By 2833	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Viewed By 2789	Recent updates on the management of autoimmune hepatitis
Viewed By 2710	Identification of high-risk subjects in nonalcoholic fatty liver disease

Cited By 99	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 42	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Cited By 42	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 40	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 38	The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future

Search